BIOMAT Database Logo BIOMAT Database Logo

2-Chlorodeoxyadenosine in the treatment of multiple myeloma. 1992

M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D003839 Deoxyadenosines Adenosine molecules which can be substituted in any position, but are lacking one hydroxyl group in the ribose part of the molecule. Adenine Deoxyribonucleosides,Adenylyldeoxyribonucleosides,Deoxyadenosine Derivatives,Deoxyribonucleosides, Adenine,Derivatives, Deoxyadenosine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015762 2-Chloroadenosine 2-Chloroadenosine. A metabolically stable analog of adenosine which acts as an adenosine receptor agonist. The compound has a potent effect on the peripheral and central nervous system. 2 Chloroadenosine

Related Publications

M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
2-Chlorodeoxyadenosine for multiple myeloma.
February 1993, Blood,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
2-Chlorodeoxyadenosine and multiple myeloma.
September 1994, European journal of haematology,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
2-Chlorodeoxyadenosine in psoriasis treatment.
May 1995, Annals of oncology : official journal of the European Society for Medical Oncology,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
2-Chlorodeoxyadenosine treatment of lymphoma.
January 1996, Cancer treatment and research,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
2-Chlorodeoxyadenosine treatment in the Sezary syndrome.
February 1997, Blood,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
Listeriosis after 2-chlorodeoxyadenosine treatment.
March 1993, The New England journal of medicine,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
Comparison of the effects of 2-chlorodeoxyadenosine and melphalan myeloma cell lines.
February 1996, Leukemia research,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
Treatment of scleromyxedema with 2-chlorodeoxyadenosine.
August 1996, Journal of the American Academy of Dermatology,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
2-Chlorodeoxyadenosine treatment of lymphoid malignancies.
February 1992, Blood,
M A Dimopoulos, and H M Kantarjian, and E H Estey, and R Alexanian
2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia.
January 1993, Cancer investigation,
Copied contents to your clipboard!